XML 27 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2018
Apr. 01, 2017
Apr. 02, 2016
Cash Flows from Operating Activities:      
Net income (loss) $ 45,572 $ (26,268) $ (55,579)
Non-cash items:      
Depreciation and amortization 89,247 89,733 89,911
Impairment of assets 2,673 75,348 101,243
Stock-based compensation expense 13,025 9,150 6,949
Gain on divestiture (8,000) 0 0
Deferred tax benefit (5,828) (6,800) (1,038)
Unrealized (gain) loss from hedging activities (649) 517 (2,645)
Changes in fair value of contingent consideration 0 0 (4,727)
Provision for losses on accounts receivable and inventory 2,639 11,381 13,053
Other non-cash operating activities 1,692 860 899
Change in operating assets and liabilities:      
Change in accounts receivable 5,087 3,155 (10,328)
Change in inventories 14,385 (1,552) 11,896
Change in prepaid income taxes 1,436 1,395 (651)
Change in other assets and other liabilities 17,670 (18,253) 3,121
Change in accounts payable and accrued expenses 41,401 21,072 (30,239)
Net cash provided by operating activities 220,350 159,738 121,865
Cash Flows from Investing Activities:      
Capital expenditures (74,799) (76,135) (102,405)
Proceeds from divestiture 9,000 0 0
Proceeds from sale of property, plant and equipment 2,758 2,822 637
Other acquisitions and investments 0 0 (3,000)
Net cash used in investing activities (63,041) (73,313) (104,768)
Cash Flows from Financing Activities:      
Repayment of term loan borrowings (61,654) (42,683) (21,342)
Net increase (decrease) in short-term loans 671 (50,727) 2,272
Proceeds from employee stock purchase plan 3,246 3,560 4,341
Proceeds from exercise of stock options 37,094 29,437 14,032
Share repurchases (100,000) 0 (60,984)
Other financing activities 0 0 (943)
Net cash used in financing activities (120,643) (60,413) (62,624)
Effect of exchange rates on cash and cash equivalents 3,939 (1,571) (12)
Net Change in Cash and Cash Equivalents 40,605 24,441 (45,539)
Cash and Cash Equivalents at Beginning of Year 139,564 115,123 160,662
Cash and Cash Equivalents at End of Year 180,169 139,564 115,123
Supplemental Disclosures of Cash Flow Information:      
Interest paid 7,663 7,850 8,511
Income taxes paid 9,083 6,957 7,829
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 8,963 $ 6,255 $ 9,663